Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme ...
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study ...
New results on Pfizer's Lyme disease vaccine, how the Middle East conflict could strain drug supply chains, and more biotech ...
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 ...
An experimental vaccine from Pfizer and Valneva reduced the risk of developing Lyme disease by more than 70%, according to ...
Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, though ...
Pfizer (NYSE:PFE) has started a Phase 1 trial of a new tafamidis tablet formulation aimed at improving manufacturing ...
In early March 2026, Pfizer reported past Phase 2 trial results showing its investigational trispecific antibody tilrekimig ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results